Engineered immune cells take on Hard-to-Treat cervical cancer
NCT ID NCT03362619
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for people with advanced or recurrent cervical cancer linked to high-risk HPV. The treatment uses specially engineered immune cells (CC-EIEs) designed to target and attack the cancer. Participants receive several infusions of these cells, and researchers monitor safety and whether the tumors shrink or stabilize.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered immune cells (CC-EIEs)
What this could lead to
If successful, this approach could offer a new treatment option for advanced or recurrent cervical cancer that is hard to treat with standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the treatment may not work or could cause significant side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••